Xencor, Inc. (NASDAQ:XNCR) CEO Bassil I. Dahiyat Sells 49,278 Shares

Xencor, Inc. (NASDAQ:XNCR) CEO Bassil I. Dahiyat sold 49,278 shares of the stock in a transaction dated Thursday, November 21st. The shares were sold at an average price of $24.07, for a total value of $1,186,121.46. Following the completion of the transaction, the chief executive officer now owns 352,615 shares in the company, valued at approximately $8,487,443.05. The trade was a 12.26 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Xencor Trading Up 4.2 %

Shares of Xencor stock opened at $26.06 on Tuesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.23 and a current ratio of 6.23. The company has a market capitalization of $1.82 billion, a P/E ratio of -8.21 and a beta of 0.66. Xencor, Inc. has a 1 year low of $15.31 and a 1 year high of $26.84. The company’s fifty day moving average is $21.47 and its two-hundred day moving average is $20.37.

Xencor (NASDAQ:XNCR) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.98) by $0.27. The firm had revenue of $10.70 million for the quarter, compared to analyst estimates of $14.59 million. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The business’s revenue was down 81.9% on a year-over-year basis. During the same quarter last year, the company posted ($0.40) earnings per share. Analysts forecast that Xencor, Inc. will post -3.71 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have commented on XNCR. JPMorgan Chase & Co. increased their price target on shares of Xencor from $27.00 to $28.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Wedbush reaffirmed an “outperform” rating and issued a $38.00 target price on shares of Xencor in a research report on Thursday, November 7th. BMO Capital Markets reissued an “outperform” rating and issued a $34.00 price target (up from $32.00) on shares of Xencor in a research report on Friday, November 8th. Finally, Royal Bank of Canada raised their price objective on Xencor from $31.00 to $34.00 and gave the stock an “outperform” rating in a report on Thursday, September 26th. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Xencor currently has an average rating of “Moderate Buy” and a consensus target price of $35.75.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Primecap Management Co. CA lifted its holdings in shares of Xencor by 0.3% during the second quarter. Primecap Management Co. CA now owns 9,116,202 shares of the biopharmaceutical company’s stock worth $172,570,000 after purchasing an additional 25,495 shares during the period. Vanguard Group Inc. raised its position in Xencor by 3.6% during the 1st quarter. Vanguard Group Inc. now owns 7,011,042 shares of the biopharmaceutical company’s stock worth $155,154,000 after buying an additional 243,793 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of Xencor by 9.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,819,656 shares of the biopharmaceutical company’s stock worth $84,530,000 after acquiring an additional 335,881 shares during the period. Point72 Asset Management L.P. boosted its holdings in shares of Xencor by 147.3% in the third quarter. Point72 Asset Management L.P. now owns 3,120,229 shares of the biopharmaceutical company’s stock valued at $62,748,000 after acquiring an additional 1,858,440 shares in the last quarter. Finally, Logos Global Management LP increased its stake in shares of Xencor by 130.8% during the second quarter. Logos Global Management LP now owns 1,500,000 shares of the biopharmaceutical company’s stock worth $28,395,000 after acquiring an additional 850,000 shares during the period.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.